Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSV-tk + Valacyclovir Gene Therapy in Recurrent Glioblastoma Multiforme
NCT03596086Phase 2Recruiting
- Start
- Dec 2017
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of aglatimagene besadenovec in glioblastoma multiforme (GBM), anaplastic astrocytoma (AA). Started Dec 2017; status: recruiting.
02
Drugs
aglatimagene besadenovec
03
Conditions
glioblastoma multiforme (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NCT03596086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03596086.